Telmisartan provides better renal protection than valsartan in a rat model of metabolic syndrome.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  American Journal of Hypertension

• Publication date

  2011-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/ajh.2011.34PMID 21415842PMCID PMC3721747
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of renin–angiotensin system blockade on the islet morphology and function in rats with long-term high-fat diet

  2013cited by this paper
• Tempol or candesartan prevents high-fat diet-induced hypertension and renal damage in spontaneously hypertensive rats.

  2010cited by this paper
• HDAC Inhibition Attenuates Inflammatory, Hypertrophic, and Hypertensive Responses in Spontaneously Hypertensive Rats

  2010cited by this paper
• Induction of hemeoxygenase-1 attenuates the hypertension and renal inflammation in spontaneously hypertensive rats.

  2010cited by this paper
• Comparison of purple carrot juice and β-carotene in a high-carbohydrate, high-fat diet-fed rat model of the metabolic syndrome.

  2010cited by this paper
• Peroxisome proliferator-activated receptor-α activator fenofibrate prevents high-fat diet-induced renal lipotoxicity in spontaneously hypertensive rats

  2009cited by this paper
• Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension.

  2009cited by this paper
• Suppression of experimental autoimmune uveitis by angiotensin II type 1 receptor blocker telmisartan.

  2009cited by this paper
• Telmisartan-Induced Inhibition of Vascular Cell Proliferation Beyond Angiotensin Receptor Blockade and Peroxisome Proliferator-Activated Receptor-γ Activation

  2009cited by this paper
• Obesity is the major contributor to vascular dysfunction and inflammation in high-fat diet hypertensive rats.

  2009cited by this paper
• Effect of the HMG-CoA Reductase Inhibitor Rosuvastatin on Early Chronic Kidney Injury in Obese Zucker Rats Fed With an Atherogenic Diet

  2009cited by this paper
• Telmisartan but not valsartan inhibits TGF-β-mediated accumulation of extracellular matrix via activation of PPARγ

  2008cited by this paper
• Endothelial Dysfunction and the Development of Renal Injury in Spontaneously Hypertensive Rats Fed a High-Fat Diet

  2008cited by this paper
• Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.

  2008cited by this paper
• Simvastatin and Tempol Protect Against Endothelial Dysfunction and Renal Injury in a Model of Obesity and Hypertension

  2008cited by this paper
• Interactions between oxidative stress and inflammation in salt-sensitive hypertension.

  2007cited by this paper
• Effects of pioglitazone on increases in visceral fat accumulation and oxidative stress in spontaneously hypertensive hyperlipidemic rats fed a high-fat diet and sucrose solution.

  2007cited by this paper
• Chronic sodium hydrosulfide treatment decreases medial thickening of intramyocardial coronary arterioles, interstitial fibrosis, and ROS production in spontaneously hypertensive rats.

  2007cited by this paper
• Telmisartan, its potential therapeutic implications in cardiometabolic disorders.

  2006cited by this paper
• Telmisartan But Not Valsartan Increases Caloric Expenditure and Protects Against Weight Gain and Hepatic Steatosis

  2006cited by this paper
• Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors.

  2006cited by this paper
• Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers.

  2005cited by this paper
• Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts.

  2005cited by this paper
• Obesity and prevalent and incident CKD: the Hypertension Detection and Follow-Up Program.

  2005cited by this paper
• Identification of Telmisartan as a Unique Angiotensin II: Receptor Antagonist With Selective PPARγ–Modulating Activity

  2004cited by this paper
• Management of the metabolic syndrome.

  2004cited by this paper
• Effects of pioglitazone on expressions of matrix metalloproteinases 2 and 9 in kidneys of diabetic rats.

  2004cited by this paper
• Altered kidney CYP2C and cyclooxygenase-2 levels are associated with obesity-related albuminuria.

  2004cited by this paper
• Angiotensin Type 1 Receptor Blockers Induce Peroxisome Proliferator–Activated Receptor-γ Activity

  2004cited by this paper
• Comparison of renal morphology in the Streptozotocin and the SHR/N-cp models of diabetes

  2004cited by this paper
• Pleiotropic actions of PPAR gamma activators thiazolidinediones in cardiovascular diseases.

  2004cited by this paper
• ARBs and target organ protection

  2004cited by this paper
• Attitudes of preclinical medical students towards caring for chronically ill and dying patients: does palliative care teaching make a difference?

  2004cited by this paper
• Insulin and insulin resistance: impact on blood pressure and cardiovascular disease.

  2004cited by this paper
• Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells.

  2004cited by this paper
• Atherosclerosis in Type 2 Diabetes Mellitus: The Role of Insulin Resistance

  2003cited by this paper
• Renal Processing of Albumin in Diabetes and Hypertension in Rats

  2003cited by this paper
• Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.

  2003cited by this paper
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

  2002cited by this paper
• Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus: A Blood Pressure–Independent Effect

  2002cited by this paper

• Unveiling the molecular mechanism of diosmin to resolve cardiovascular dysfunction and remodeling in hypertension.

  2025cites this paper
• Three-Year Cardiovascular Outcomes of Telmisartan in Patients with Hypertension: An Electronic Health Record-Based Cohort Study.

  2024cites this paper
• Impact of time‐restricted feeding on kidney injury in male rats with experimental metabolic syndrome

  2023influential citation
• Angiotensin II inhibition increases diuresis during acute sympathetic activation in intact and denervated kidneys in rats with chronic myocardial infarction

  2022cites this paper
• EVALUATION OF THE POSSIBLE PROTECTIVE EFFECTS OF CAPTOPRIL AND VALSARTAN ON METHOTREXATE-INDUCED HEPATOTOXICITY IN ALBINO RATS

  2019cites this paper
• Impact of obesity as an independent risk factor for the development of renal injury: implications from rat models of obesity.

  2019cites this paper
• Telmisartan is effective to ameliorate metabolic syndrome in rat model – a preclinical report

  2018cites this paper
• Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Dovepress

  2018cites this paper
• Telmisartan and thiorphan combination treatment attenuates fibrosis and apoptosis in preventing diabetic cardiomyopathy

  2018cites this paper
• Development and biological evaluation of vesicles containing bile salt of telmisartan for the treatment of diabetic nephropathy

  2018cites this paper
• Comparative Renal Protective Effects of Canagliflozin and Telmisartan in a Rat Model of Diabetic Nephropathy

  2016cites this paper
• Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease.

  2016cites this paper
• Effects of telmisartan and olmesartan on insulin sensitivity and renal function in spontaneously hypertensive rats fed a high fat diet.

  2016cites this paper
• Valsartan attenuates cardiac and renal hypertrophy in rats with experimental cardiorenal syndrome possibly through down-regulating galectin-3 signaling.

  2016cites this paper
• Effect of valsartan on cardiac senescence and apoptosis in a rat model of cardiotoxicity.

  2016cites this paper
• PPARs Link Early Life Nutritional Insults to Later Programmed Hypertension and Metabolic Syndrome

  2015cites this paper
• Antihypertensive and anti‐inflammatory actions of combined azilsartan and chlorthalidone in Dahl salt‐sensitive rats on a high‐fat, high‐salt diet

  2014cites this paper
• Azilsartan Decreases Renal and Cardiovascular Injury in the Spontaneously Hypertensive Obese Rat

  2014cites this paper
• Strong improvement of apolipoprotein E/low-density lipoprotein receptor signals by telmisartan in poststroke spontaneously hypertensive stroke resistant.

  2014cites this paper
• Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.

  2013cites this paper
• Telmisartan/Hydrochlorothiazide Combination Therapy for the Treatment of Hypertension: A Pooled Analysis in Older and Younger Patients

  2013cites this paper
• Telmisartan Protects against Vascular Dysfunction with Peroxisome Proliferator-Activated Receptor-γ Activation in Hypertensive 5/6 Nephrectomized Rats

  2013cites this paper
• Telmisartan in the management of diabetic nephropathy: a contemporary view.

  2012cites this paper
• Sympathoinhibitory effects of telmisartan through the reduction of oxidative stress in the rostral ventrolateral medulla of obesity-induced hypertensive rats

  2012cites this paper
• Telmisartan as metabolic modulator: a new perspective in sports doping?

  2012cites this paper
• Triple drug combination of telmisartan, amlodipine and hydrochlorothiazide in the treatment of essential hypertension

  2012cites this paper
• Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats.

  2012cites this paper
• Preclinical and Clinical Effects of RAS Inhibition with a Focus on Telmisartan

  2012cites this paper
• Emerging benefits of AT1 receptor antagonists with pleiotropic anti-inflammatory activity.

  2011cites this paper
• Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Dovepress

  2010cites this paper
• International Journal of Nephrology and Renovascular Disease Dovepress Renoprotective Effects of Telmisartan after Unilateral Renal Ablation in Rats

  year unknowncites this paper